Compare Firy Inc. (FIRY) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Firy Inc. trades at $11.27 (market cap $206.28M), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 4.7× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Firy Inc. for 13 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FIRY | MRVI | |
|---|---|---|
Market Cap | $206.28M | $972.90M |
Volume | 112,784 | 4,325,710 |
Sector | Technology | Health |
52-Week High | $13.10 | $9.00 |
52-Week Low | $2.28 | $2.83 |
Typical Hold Time | 13 Days | 0 Days |
Enterprise Value | $174.88M | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY (formerly Skillz Inc.) trades at $11.17, down 9.85% in the last session. The technical outlook is bullish based on moving averages, though oscillators are neutral. Fundamentally, the company shows persistent losses with a net income margin of -60.23% despite an 87.76% gross margin. Recent developments include a $719 million legal victory and board additions, but cash burn remains a concern with negative operating cash flow of $68.93 million in 2025.
The outlook is cautious. While the legal win and strategic shifts offer potential upside, sustained losses and negative cash flow pose significant risks. Analyst sentiment is mixed with 60% hold ratings. Key catalysts include the collection of the legal judgment and improved operational efficiency, but investors face substantial execution and liquidity risks.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
